Completed PHASE1 INTERVENTIONAL NCT00006480

Biological Therapy and Gene Therapy in Treating Children With Recurrent or Refractory Neuroblastoma

Phase I Study to Evaluate the Safety of Cellular Immunotherapy for Recurrent/Refractory Neuroblastoma Using Genetically-Modified Autologous CD8+ T Cell Clones

Sponsor: Fred Hutchinson Cancer Center

Conditions Neuroblastoma

Interventions aldesleukin chemotherapy ganciclovir therapeutic autologous lymphocytes

Updated 6 times since 2017 Last updated: Sep 17, 2010 Started: May 31, 2000 Completion: Mar 31, 2005

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Neuroblastoma and is currently completed. Fred Hutchinson Cancer Center leads this study, which shows 6 recorded versions since 2000 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2022 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — May 2022 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE1

First recorded

May 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Data source: Fred Hutchinson Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Duarte, United States
• Seattle, United States